Sugimachi K, Okamura T, Furusawa M, Saku M, Noda S, Matsusaka T, Teraoka H, Toda T, Oka N, Inokuchi K
Second Department of Surgery, Faculty of Medicine, Kyushu University.
Gan To Kagaku Ryoho. 1988 Oct;15(10):2953-7.
A prospective randomized and comparative study of FT-207 and UFT was performed for cases of Stage IV gastric cancer involving long-term cancer chemotherapy after surgery. Immediately after the surgery, the subjects were randomly divided into two groups: A group treated by MMC and FT-207: and B group treated by MMC and UFT. From a total of 54 cases, 8 cases were excluded, so that A group consisted of 24 subjects and B group of 22 subjects. There were no differences in background factors between the two groups. In a comparison of all the cases, B group revealed a significantly higher survival rate than A group. These results indicated that the simultaneous use of MMC and UFT was effective as a long-term cancer chemotherapy after surgery for patients with Stage IV gastric cancer.
对IV期胃癌患者术后长期癌症化疗进行了FT - 207与优福定（UFT）的前瞻性随机对照研究。手术后，受试者立即随机分为两组：A组接受丝裂霉素（MMC）和FT - 207治疗；B组接受MMC和优福定治疗。54例患者中排除8例，A组有24例受试者，B组有22例受试者。两组的背景因素无差异。在所有病例的比较中，B组的生存率显著高于A组。这些结果表明，MMC与优福定联合使用作为IV期胃癌患者术后长期癌症化疗是有效的。
